Semantic Scholar uses AI to extract papers important to this topic.
Abstract 1. Asunaprevir (ASV, BMS-650032), a highly selective and potent NS3 protease inhibitor, is currently under development… Expand Asunaprevir (ASV; BMS-650032), a low nanomolar inhibitor of the hepatitis C virus (HCV) NS3 protease, is currently under… Expand Asunaprevir, a second-generation NS3 protease inhibitor of hepatitis C virus (HCV), exhibits strong antiviral activity against… Expand The discovery of asunaprevir (BMS-650032, 24) is described. This tripeptidic acylsulfonamide inhibitor of the NS3/4A enzyme is… Expand Asunaprevir (BMS‐650032, ASV) is a potent, selective hepatitis C virus (HCV) NS3 protease inhibitor in clinical evaluation for… Expand ABSTRACT Asunaprevir (ASV; BMS-650032) is a hepatitis C virus (HCV) NS3 protease inhibitor that has demonstrated efficacy in… Expand Background and Aims: The chemokine IP-10 (or CXCL10) has been identified to be a negative predictor for response to pegylated… Expand 3. PR plus BOC for 44 weeks (BOC/PR48). Primary endpoint was SVR 24 wks post-therapy (Roche TaqMan LLD = 9.3 IU/mL). Results: SVR… Expand